Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic

María Fernández-Velasco1, Angélica Rueda, Nicoletta Rizzi

  • 1Institut National de la Santé et de la Recherche Médicale, U637, Université de Montpellier, Montpellier, France.

Circulation Research
|December 20, 2008
PubMed

Insights

Mutations in the cardiac ryanodine receptor (RyR2) cause catecholaminergic polymorphic ventricular tachycardia by increasing RyR2

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Cardiac ryanodine receptor (RyR2) mutations are linked to catecholaminergic polymorphic ventricular tachycardia (CPVT).
  • Altered intracellular calcium (Ca2+) handling is implicated in CPVT pathogenesis.

Purpose of the Study:

  • To investigate the Ca2+ handling defect in cardiomyocytes with the RyR2(R4496C) mutation.
  • To elucidate the mechanism by which RyR2 mutations lead to cardiac arrhythmias.

Main Methods:

  • Cardiomyocytes from heterozygous RyR2(R4496C) knock-in mice and wild-type littermates were used.
  • Intracellular Ca2+ ([Ca2+]i) transients were measured using confocal microscopy and fluo-3 fluorescence.
  • Ca2+ release and spark frequency were analyzed under various stimulation rates and beta-adrenergic stimulation.

Main Results:

  • RyR2(R4496C) cardiomyocytes exhibited abnormal diastolic Ca2+ release, manifesting as Ca2+ waves and delayed afterdepolarizations.
  • Increased Ca2+ spark frequency and enhanced Ca2+ sensitivity of RyR2(R4496C) were observed.
  • Beta-adrenergic stimulation increased Ca2+ transient amplitude and spark frequency similarly in both mutant and wild-type cells, indicating unaltered beta-adrenergic sensitivity.

Conclusions:

  • The RyR2(R4496C) mutation increases RyR2 Ca2+ sensitivity, leading to arrhythmogenic diastolic Ca2+ release.
  • This diastolic Ca2+ release lowers the threshold for triggered activity, contributing to CPVT.
  • The study identifies increased Ca2+ sensitivity as the key arrhythmogenic mechanism of the RyR2(R4496C) mutation.

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Dysrhythmias II: Classification of Tachyarrhythmias01:28

Dysrhythmias II: Classification of Tachyarrhythmias

Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...